139 related articles for article (PubMed ID: 30687992)
1. Oral ribavirin for paramyxovirus infection after alemtuzumab-containing reduced-intensity conditioning HCT regimen.
Dreyzin A; Michaels MG; Vander Lugt MT; Szabolcs P
Pediatr Transplant; 2019 Mar; 23(2):e13358. PubMed ID: 30687992
[TBL] [Abstract][Full Text] [Related]
2. Pre-emptive oral ribavirin therapy of paramyxovirus infections after haematopoietic stem cell transplantation: a pilot study.
Chakrabarti S; Collingham KE; Holder K; Fegan CD; Osman H; Milligan DW
Bone Marrow Transplant; 2001 Oct; 28(8):759-63. PubMed ID: 11781627
[TBL] [Abstract][Full Text] [Related]
3. A risk-adapted approach to treating respiratory syncytial virus and human parainfluenza virus in allogeneic stem cell transplantation recipients with oral ribavirin therapy: A pilot study.
Piñana JL; Hernández-Boluda JC; Calabuig M; Ballester I; Marín M; Madrid S; Teruel A; Terol MJ; Navarro D; Solano C
Transpl Infect Dis; 2017 Aug; 19(4):. PubMed ID: 28544152
[TBL] [Abstract][Full Text] [Related]
4. Oral Versus Aerosolized Ribavirin for the Treatment of Respiratory Syncytial Virus Infections in Hematopoietic Cell Transplant Recipients.
Foolad F; Aitken SL; Shigle TL; Prayag A; Ghantoji S; Ariza-Heredia E; Chemaly RF
Clin Infect Dis; 2019 May; 68(10):1641-1649. PubMed ID: 30202920
[TBL] [Abstract][Full Text] [Related]
5. Ribavirin therapy in bone marrow transplant recipients with viral respiratory tract infections.
Sparrelid E; Ljungman P; Ekelöf-Andström E; Aschan J; Ringdén O; Winiarski J; Wåhlin B; Andersson J
Bone Marrow Transplant; 1997 May; 19(9):905-8. PubMed ID: 9156264
[TBL] [Abstract][Full Text] [Related]
6. Effective use of oral ribavirin for respiratory syncytial viral infections in allogeneic haematopoietic stem cell transplant recipients.
Gorcea CM; Tholouli E; Turner A; Saif M; Davies E; Battersby E; Dignan FL
J Hosp Infect; 2017 Feb; 95(2):214-217. PubMed ID: 28077243
[TBL] [Abstract][Full Text] [Related]
7. Long-term therapy with aerosolized ribavirin for parainfluenza 3 virus respiratory tract infection in an infant with severe combined immunodeficiency.
Stankova J; Carret AS; Moore D; McCusker C; Mitchell D; Davis M; Mazer B; Jabado N
Pediatr Transplant; 2007 Mar; 11(2):209-13. PubMed ID: 17300503
[TBL] [Abstract][Full Text] [Related]
8. Clinical Outcomes of Paramyxovirus Infections in Lung Transplant Recipients Treated With Oral Ribavirin: A Two-Center Case Series.
Garcia B; Sharma N; Johnson K; Salgado J; Wille K
Exp Clin Transplant; 2019 Jun; 17(3):393-397. PubMed ID: 29108516
[TBL] [Abstract][Full Text] [Related]
9. Immune modulatory activity of ribavirin for serious human metapneumovirus disease: early i.v. therapy may improve outcomes in immunosuppressed SCT recipients.
Safdar A
Bone Marrow Transplant; 2008 Apr; 41(8):707-8. PubMed ID: 18347567
[No Abstract] [Full Text] [Related]
10. Oral ribavirin therapy for respiratory syncytial virus infections in moderately to severely immunocompromised patients.
Marcelin JR; Wilson JW; Razonable RR;
Transpl Infect Dis; 2014 Apr; 16(2):242-50. PubMed ID: 24621016
[TBL] [Abstract][Full Text] [Related]
11. Human parainfluenza virus infection after hematopoietic stem cell transplantation: risk factors, management, mortality, and changes over time.
Ustun C; Slabý J; Shanley RM; Vydra J; Smith AR; Wagner JE; Weisdorf DJ; Young JA
Biol Blood Marrow Transplant; 2012 Oct; 18(10):1580-8. PubMed ID: 22531491
[TBL] [Abstract][Full Text] [Related]
12. Oral ribavirin is a highly effective treatment for lower respiratory tract infections due to respiratory syncytial virus or parainfluenza after allogeneic stem cell transplantation.
Stamouli M; Tsonis I; Gkirkas K; Economopoulou C; Siafakas N; Pournaras S; Antoniadou A; Chondropoulos S; Karagiannidi A; Meletiadis J; Gigantes S; Baltadakis I; Goussetis E; Karakasis D; Tsirigotis P
Bone Marrow Transplant; 2021 Feb; 56(2):511-513. PubMed ID: 32772044
[No Abstract] [Full Text] [Related]
13. Respiratory virus infections in transplant recipients after reduced-intensity conditioning with Campath-1H: high incidence but low mortality.
Chakrabarti S; Avivi I; Mackinnon S; Ward K; Kottaridis PD; Osman H; Waldmann H; Hale G; Fegan CD; Yong K; Goldstone AH; Linch DC; Milligan DW
Br J Haematol; 2002 Dec; 119(4):1125-32. PubMed ID: 12472597
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of oral ribavirin in hematologic disease patients with paramyxovirus infection: analytic strategy using propensity scores.
Park SY; Baek S; Lee SO; Choi SH; Kim YS; Woo JH; Sung H; Kim MN; Kim DY; Lee JH; Lee JH; Lee KH; Kim SH
Antimicrob Agents Chemother; 2013 Feb; 57(2):983-9. PubMed ID: 23229488
[TBL] [Abstract][Full Text] [Related]
15. Respiratory syncytial virus and parainfluenza virus infections in the immunocompromised host.
Wendt CH; Hertz MI
Semin Respir Infect; 1995 Dec; 10(4):224-31. PubMed ID: 8668850
[TBL] [Abstract][Full Text] [Related]
16. A multi-drug regimen for respiratory syncytial virus and parainfluenza virus infections in adult lung and heart-lung transplant recipients.
Liu V; Dhillon GS; Weill D
Transpl Infect Dis; 2010 Feb; 12(1):38-44. PubMed ID: 19761558
[TBL] [Abstract][Full Text] [Related]
17. Comparative effectiveness of aerosolized versus oral ribavirin for the treatment of respiratory syncytial virus infections: A single-center retrospective cohort study and review of the literature.
Trang TP; Whalen M; Hilts-Horeczko A; Doernberg SB; Liu C
Transpl Infect Dis; 2018 Apr; 20(2):e12844. PubMed ID: 29360277
[TBL] [Abstract][Full Text] [Related]
18. Treatment of respiratory syncytial virus infection in haemopoietic stem cell transplant recipients with aerosolized ribavirin and the humanized monoclonal antibody palivizumab: a single centre experience.
Tsitsikas DA; Oakervee H; Cavenagh JD; Gribben J; Agrawal SG; Mattes FM
Br J Haematol; 2009 Sep; 146(5):574-6. PubMed ID: 19538531
[No Abstract] [Full Text] [Related]
19. The impact of RSV, adenovirus, influenza, and parainfluenza infection in pediatric patients receiving stem cell transplant, solid organ transplant, or cancer chemotherapy.
Lo MS; Lee GM; Gunawardane N; Burchett SK; Lachenauer CS; Lehmann LE
Pediatr Transplant; 2013 Mar; 17(2):133-43. PubMed ID: 23228170
[TBL] [Abstract][Full Text] [Related]
20. Management of respiratory viral infections in hematopoietic cell transplant recipients and patients with hematologic malignancies.
Chemaly RF; Shah DP; Boeckh MJ
Clin Infect Dis; 2014 Nov; 59 Suppl 5(Suppl 5):S344-51. PubMed ID: 25352629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
